siRNA knockdown of DCLK-isoform2 resulted in greater CD8+ T cell activation and reduced pancreatic cancer cell viability—suggesting DCLK-isoform2 is a novel therapeutic target in pancreatic cancer. Here, DCLK1 is linked to pancreatic neoplasm.